A Comparison of Lipo-doxorubicin and Doxorubicin for Bladder Cancer

This report analyzes the therapeutic efficacy of Lipo-doxorubicin compared to doxorubicin in treating bladder cancer. Doxorubicin, a common chemotherapy drug, faces limitations due to side effects and short intracellular retention. The study explores liposomal doxorubicin (Lipodox) as a drug delivery system to improve pharmacokinetics and drug dispersion. Methods include cell line cultures, cell viability measurements, fluoroscopic observations, flow cytometry, and orthotopic tumor implantation in mice. The findings highlight differences in intracellular dispersion pathways between Doxorubicin and Lipodox, suggesting Lipodox has superior cytotoxic efficacy and therapeutic effects in transitional cell carcinoma cells, offering a basis for further research into Lipodox as an alternative intravesical therapeutic regimen for bladder cancer patients. Desklib provides a platform to access similar solved assignments and study resources.

Comparison of therapeutic efficacy of lipo-
doxorubicin and doxorubicin in treating bladder
cancer.
INTRODUCTION
Doxorubicin is generally a cytotoxic
anthracycline antibiotic that is isolated from
Streptomyces peucetius and can exerts its
antitumor effects through inhibiting the
topoisomerase II. In order to treat the bladder
cancer the Doxorubicin is most commonly used
but with having more side effects as well as
shorter intracellular retention time hamper its
clinical application. In this, the liposomes are
generally conceived as a delivery systems of the
drugs in order to modify the pharmacokinetics
and dispersion of the drugs with having a goal of
HYPOTHESIS
“To analyze the comparison of
therapeutic efficacy of Lipo-doxorubicin and
doxorubicin in treating the bladder cancer among
people across world.”
METHODS
There are the methods that are used to
analyze the bladder cancer such as culture of the
cell lines, specific chemicals used, measurement
of cell viability, the fluoroscopic observations of
intracellular distribution of both Lipodox and
Doxorubicin in the TCC cells, alterations in the
concentration of the intracellular drug can be
evaluated by flow cytometry, implantation of
MBT-2 orthotopic tumor, an intravesical
treatment of orthotopic bladder tumors by using
both Lipodox and Doxorubicin and finally the
statistical analysis.
Figure 1 intracellular distribution of (A,B) doxorubicin
and (C,D) Lipodox after treatment of drug for 2 hours.
Figure 2 Serial alterations of intracellular drug
fluorescence of Doxorubicin and Lipodox in MBT-2
tumor cells after 2 hours of treatment.
DISCUSSION
The Doxorubicin is generally one of the
most commonly used wide spectrum the
chemotherapy drugs. It has been clinically applied
for many years in order to prevent the tumor of
bladder recurrence by simply intravesical
instillation with having an average response rate of
about 45%. In this, an encapsulation of the
Doxorubicin in the PEG-coated liposomes was
specifically developed in order to improve the
efficacy and safety of the conventional doxorubicin.
In this, the liposomes after the pharmacological and
the pharmacokinetics parameters of conventional
doxorubicin so that the delivery of the drug to the
tumor cells can be improved while the toxicity of the
conventional doxorubicin is reduced. Among both
humans and animals, the pharmacokinetics benefits
of the lipodox can involve an enhanced region under
the plasma concentration-time curve, the longer
dispersions half-life, smaller volume of the
distribution and the decreased authorization.
Within the clinical models, the Lipodox is generally
produced the remission as well as cure against
various cancers containing the tumors of breast,
ovaries, lung, colon, bladder and many more. It is
specifically found to be quite effective as an
adjuvant therapy with having the tolerable adverse
reactions.
CONCLUSION
It is analyzed that the incidence of bladder cancer
is quite higher in the developed countries, but the rate of
the prevalence is reducing and is generally in less
developed and the developing countries it is raising. In the
above discussion, it is demonstrated the differences among
the intracellular dispersion pathways among the
Doxorubicin and Lipodox, that can provide the Lipodox
superior cytotoxic efficacy in the transitional cell
carcinoma cells as well as the higher therapeutic effects
and its marginal survival advantages in the orthotopic
neogrowth of the mice organism. Such outcomes can give a
useful basis for further study of the Lipodox as an
alternative intravesical therapeutic regimen for the cancer
of bladder in the patients.